The first is activating mutations in oncogenes such as BRAF or NRAS. BRAF mutations are found in 50% of melanoma patients (Figure 2) and the V600E mutation accounts for approximately 75% of all BRAF mutations detected in cutaneous melanoma [9]. This evidence concerns the gene BRAF and melanoma.